Business Context and Reporting Period
Company: Akers Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 9, 2020
Reporting Period: Event-based report regarding corporate governance actions taken on September 9, 2020.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the implementation of a shareholder rights plan.
Material Changes and Corporate Actions
The Board of Directors declared a dividend of one preferred share purchase right (a "Right") for each issued and outstanding share of Common Stock. Key terms include:
- Record Date: September 21, 2020.
- Underlying Security: Each Right entitles the holder to purchase 1/1,000th of a share of Series E Junior Participating Preferred Stock.
- Purchase Price: $15.00 per Right (subject to adjustment).
- Trigger Event: Rights become exercisable upon the earlier of (i) 10 business days after a person acquires 10% or more of outstanding Common Stock ("Acquiring Person"), or (ii) 10 business days after the commencement of a tender offer that would result in an Acquiring Person.
- Expiration: Rights expire on September 8, 2021, unless redeemed, exchanged, or terminated earlier.
- Redemption: The Board may redeem Rights in whole at $0.001 per Right at any time before an Acquiring Person emerges.
- Flip-In Provision: If an Acquiring Person emerges, holders (excluding the Acquirer) may exercise Rights to receive Common Stock with a value equal to two times the exercise price.
Guidance, Outlook, and Risks
Management Commentary: The filing details the adoption of a "poison pill" strategy to protect shareholder interests against unsolicited acquisition attempts. The Board retains the discretion to redeem the Rights or exchange them for Common Stock under specific conditions.
Risks and Contingencies:
- Acquisition Deterrence: The plan is designed to make hostile takeovers prohibitively expensive or dilutive for potential acquirers.
- Derivatives: The definition of "Beneficial Ownership" includes interests created by derivative contracts, broadening the scope of the trigger.
- Amendments: The Board may amend the Rights Agreement without shareholder approval as long as the Rights remain redeemable.
Investor Verification Checklist
- Verify the current trading price of Akers Biosciences Common Stock relative to the $15.00 exercise price of the Rights.
- Confirm the Record Date (September 21, 2020) to determine eligibility for the Rights dividend.
- Review the full Rights Agreement (Exhibit 4.1) for specific exceptions to the 10% ownership threshold.
- Monitor for any Board announcements regarding the redemption of Rights or the occurrence of a "Flip-in Event."
- Check for subsequent filings regarding the Series E Junior Participating Preferred Stock designation.